Skip To Main Content
Padmanee Sharma on Muck Rack

Padmanee Sharma

As seen in: Nature, Science Magazine, The Lancet, Cell Press, Healio, HemOnc Today, Cancer Discovery, Md Anderson Cancer Center, Texas Medical Center, Odessa American and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Padmanee

Contact Padmanee, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A transferable gut microbiota–bile acid pathway programs nanomedicine pharmacokinetics and therapeutic response

|
By Mengyu Chang, Yifan Wang Verified, JongHoon Ha, Zoey R. Neale, Nadim J. Ajami, Laurence P Diggs, Ansel P. Nalin, Yifan Ma, Shiyan Dong, Abderrahman Day, Seong Dong Jeong, Annette Wu, Benjamin R. Schrank, Jared Edwards, Tianyu Wang, Xiaotian Wang, Yen-Tzu Chang, Chaoyang Tang, Anthony Lim, Michelle Torres, Weiye Deng, Sangeeta Goswami, Dadi Jiang, Albert C. Koong, Padmanee Sharma, Jennifer Wargo, Wen Jiang, Betty Kim, Yasmine M. Hoballah, Timothy Peitsch, Maurice J. Dufilho IV
| Nature Verified
Abstract The clinical efficacy of nanomedicines is often limited by hepatic sequestration, yet the endogenous programs determining this clearance state remain incompletely understood. Here we identify the gut microbiota as a regulator of nanomedicine biodistribution through bile-acid-associated programming of Kupffer cell phagocytic state.
Open in Who Shared Issue with article?

A guide to CAR T cell therapies: development, current status and future prospects

|
By Hind Rafei, Ranjan Upadhyay, Padmanee Sharma
| Nature Verified
Abstract Since the first clinical approval in 2017, chimeric antigen receptor (CAR) T cell therapy has emerged as one of the most powerful modalities for redirecting the immune response against cancer. Building on decades of foundational discoveries in T cell biology and synthetic immunoengineering, CAR T cell therapy has transformed the treatment of B cell malignancies, resulting in durable remissions in patients with B cell leukaemias, lymphomas and multiple myeloma.
Open in Who Shared Issue with article?

Programming the immunological properties of mRNA vaccines for cancer

|
By Annette Wu, Seong Dong Jeong, Benjamin R. Schrank, Betty Kim, Padmanee Sharma, Wen Jiang
| Nature Verified
Abstract Messenger RNA (mRNA) vaccines are a transformative platform for inducing antigen-specific T cell and B cell responses that are now being trialled in oncology. Here we propose an immunological framework that reconciles four axes controlling the efficacy of mRNA cancer vaccines: adjuvanticity versus immunopathology, antigen immunogenicity versus tolerance, adaptive immune memory versus exhaustion, and beneficial versus maladaptive trained immunity.
Open in Who Shared Issue with article?
See all 44 licensed articles (48 Total)